Eilon Kirson, M.D., Ph.D.

Chief Science Officer and Head of Research and Development

Dr. Eilon Kirson joined Novocure in 2002 and served as Chief Medical Officer until 2012 when he was promoted to Chief Science Officer and Head of Research and Development. Dr. Kirson has global responsibility for Novocure’s preclinical and clinical and product development programs, as well as the company’s regulatory strategy. Throughout his tenure at Novocure, Dr. Kirson has led the development of TTFields therapy from pre-clinical testing to large, multi-center phase III studies and through multiple regulatory approvals. Dr. Kirson previously served as Head of Electrophysiology at Carmel Biosensensors. Dr. Kirson received his B.Med.Sc., M.D. and Ph.D. in Biophysics from the Hebrew University and underwent his residency in neurology at Sheba Medical Center, Tel Ha-Shomer Hospital, Israel.

Print Friendly, PDF & Email